Evoke Pharma, Inc. (EVOK)
Stock Price:
$5.36 USD
-0.01 (-0.20%)
Updated Aug 12, 2020 1:40 PM EDT - Market open
Key Info
| Market Cap |
139.39M |
| Revenue (ttm) |
n/a |
| Net Income (ttm) |
-11.80M |
| Shares Out |
24.70M |
| EPS (ttm) |
-0.48 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Aug 12, 2020 |
| Last Price |
$5.36 |
| Previous Close |
$5.37 |
| Change ($) |
-0.01 |
| Change (%) |
-0.20% |
| Day's Open |
5.40 |
| Day's Range |
5.33 - 5.69 |
| Day's Volume |
759,049 |
| 52-Week Range |
0.73 - 6.06 |
More Stats
| Market Cap |
139.39M |
| Enterprise Value |
133.58M |
| Earnings Date (est) |
Nov 17, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
24.70M |
| Float |
21.89M |
| EPS (basic) |
-0.48 |
| EPS (diluted) |
-0.48 |
| FCF / Share |
-0.21 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
1.22M |
| Short Ratio |
0.26 |
| Short % of Float |
3.70% |
| Beta |
2.03 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
n/a |
| PB Ratio |
34.67 |
| Revenue |
n/a |
| Operating Income |
-11.82M |
| Net Income |
-11.80M |
| Free Cash Flow |
-5.31M |
| Net Cash |
5.82M |
| Net Cash / Share |
0.22 |
| Gross Margin |
n/a |
| Operating Margin |
n/a |
| Profit Margin |
n/a |
| FCF Margin |
n/a |
| ROA |
-92.93% |
| ROE |
-395.28% |
| ROIC |
n/a |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (1)
| Buy |
1 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Low
10.0
Current: $5.36
High
10.0
Target: 10.00
*Average 12-month price target from 1 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|
| Revenue | - | - | - | - | - | - | - | - | - |
| Operating Income | -7.15 | -8.01 | -11.23 | -10.54 | -11.82 | -13.25 | -2.60 | -2.00 | -2.41 |
| Net Income | -7.13 | -7.57 | -12.23 | -10.75 | -12.12 | -13.25 | -2.84 | -2.02 | -2.40 |
| Shares Outstanding | 22.30 | 16.60 | 14.90 | 9.34 | 6.49 | 6.03 | 2.37 | 1.12 | 1.10 |
| Earnings Per Share | -0.32 | -0.46 | -0.90 | -1.15 | -1.87 | -2.20 | -1.20 | -1.79 | -2.18 |
| Operating Cash Flow | -5.76 | -6.98 | -8.72 | -8.71 | -10.50 | -11.50 | -3.04 | -1.75 | -2.89 |
| Free Cash Flow | -5.76 | -6.98 | -8.72 | -8.71 | -10.50 | -11.50 | -3.04 | -1.75 | -2.89 |
| Cash & Equivalents | 5.66 | 5.32 | 7.68 | 9.01 | 8.69 | 14.16 | 24.20 | 0.12 | 0.87 |
| Total Debt | 0.14 | - | - | - | 4.38 | 4.32 | 2.95 | 0.98 | - |
| Net Cash / Debt | 5.53 | 5.32 | 7.68 | 9.01 | 4.31 | 9.83 | 21.24 | -0.86 | 0.87 |
| Assets | 6.40 | 5.66 | 7.94 | 9.29 | 9.53 | 15.23 | 24.99 | 0.12 | 0.91 |
| Liabilities | 2.02 | 1.63 | 5.78 | 5.51 | 6.07 | 6.04 | 3.80 | 1.55 | 0.33 |
| Book Value | 4.38 | 4.03 | 2.17 | 3.79 | 3.46 | 9.19 | 21.18 | -19.66 | -17.65 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Evoke Pharma, Inc. |
| Country |
United States |
| Employees |
5 |
| CEO |
David A. Gonyer |
Stock Information
| Ticker Symbol |
EVOK |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Drugs - Generic |
| Unique Identifier |
NASDAQ: EVOK |
| IPO Date |
September 25, 2013 |
Description
Evoke Pharma, Inc., a specialty pharmaceutical company, primarily focuses on the development of drugs for the treatment of gastroenterological disorders and diseases. It is developing Gimoti, a metoclopramide nasal spray, which is completed Phase III clinical trials for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women. The company was founded in 2007 and is headquartered in Solana Beach, California.